Skip to main content

Table 1 Baseline Characteristics

From: Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study

Study population No steatosis Steatosis only Steatosis with fibrosis p value
N = 1120 N = 484 N = 414 N = 222
Age, years 55.4 ± 9.4 52.4 ± 9.7a 59.8 ± 7.8ab < 0.001
Male, n (%) 216 (44.6%) 211 (51.0%) 104 (46.8%) 0.163
Weight, kg 61.1 ± 9.4 68.8 ± 11.8a 68.8 ± 10.7a < 0.001
Height, cm 162.1 ± 8.6 163.6 ± 8.9a 162.4 ± 8.5 0.033
BMI, kg/m2 23.2 ± 2.8 25.6 ± 3.0a 26.1 ± 3.2a < 0.001
Waist Circumference, cm 79.2 ± 7.5 85.8 ± 8.0a 87.2 ± 7.8a < 0.001
Metabolic Syndrome, n/total n (%) 174/466 (37.3%) 282/404 (69.8%) 150/221 (67.9%) < 0.001
Regular alcohol consumption, n/total n (%) 182/437 (41.6%) 183/392 (46.7%) 70/204 (34.3%) 0.014
Smoking, ever, n/total n (%) 166/420 (39.5%) 174/384 (45.3%) 70/194 (36.1%) 0.072
Regular exercise, n/total n (%) 135/383 (35.2%) 172/360 (47.8%) 78/187 (41.7%) 0.002
Hypertension, n (%) 130 (26.9%) 135 (32.6%) 97 (43.7%) < 0.001
SBP, mmHg 131.1 ± 16.7 135.0 ± 16.9a 138.3 ± 16.4a < 0.001
DBP, mmHg 84.3 ± 10.6 88.3 ± 11.2a 87.4 ± 10.6a < 0.001
Duration of diabetes, years 7.2 ± 6.9 5.5 ± 5.3a 6.1 ± 5.5 < 0.001
HbA1c, % 8.3 ± 2.1 8.7 ± 1.9a 8.0 ± 1.6b < 0.001
HbA1c, mmol/mol 67.0 ± 23.0 72.0 ± 20.8a 64.0 ± 17.5b < 0.001
KITT, %/min 2.4 ± 1.0 1.9 ± 0.8a 1.8 ± 0.7a < 0.001
Total Cholesterol, mg/dL 188.6 ± 38.5 201.8 ± 45.1a 197.7 ± 39.3a < 0.001
Triglyceride, mg/dL 115.7 ± 63.3 172.3 ± 140.0a 157.7 ± 89.2a < 0.001
HDL-C, mg/dL 54.2 ± 14.8 48.4 ± 12.2a 50.6 ± 12.8a < 0.001
LDL-C, mg/dL 110.1 ± 32.3 118.9 ± 35.7a 113.6 ± 35.3 0.002
BUN, mg/dL 17.5 ± 7.3 16.9 ± 5.0 18.7 ± 8.2b 0.005
Creatinine, mg/dL 0.8 ± 0.2 0.8 ± 0.3 0.8 ± 0.2a 0.007
eGFR (MDRD), mL/min/1.73 m2 94.5 ± 30.9 93.0 ± 28.0 88.0 ± 27.4a 0.022
Total Bilirubin, mg/dL 0.9 ± 0.3 0.8 ± 0.3 1.0 ± 0.5ab 0.002
AST, IU/L 25.0 ± 12.6 24.4 ± 8.0 36.7 ± 17.6ab < 0.001
ALT, IU/L 23.6 ± 15.9 30.5 ± 14.9a 37.0 ± 25.2ab < 0.001
Total Protein, mg/dL 7.3 ± 0.4 7.3 ± 0.4 7.4 ± 0.5ab 0.006
Albumin, mg/dL 4.3 ± 0.4 4.4 ± 0.3 4.4 ± 0.3 0.068
Platelet,/uL 210.7 ± 59.2 240.0 ± 53.4a 183.3 ± 38.6ab < 0.001
Insulin use, n (%) 47 (9.7%) 24 (5.8%) 15 (6.8%) 0.076
SU use, n (%) 240 (49.6%) 191 (46.1%) 140 (63.1%) < 0.001
Metformin use, n (%) 172 (35.5%) 156 (37.7%) 93 (41.9%) 0.270
TZD use, n (%) 57 (11.8%) 25 (6.0%) 21 (9.5%) 0.012
Statin use, n (%) 63 (13.0%) 53 (12.8%) 25 (11.3%) 0.797
Aspirin use, n (%) 62 (12.8%) 58 (14.0%) 35 (15.8%) 0.568
Carotid IMT, mm 0.75 ± 0.15 0.76 ± 0.15 0.81 ± 0.14ab < 0.001
Presence of plaque, n (%) 153 (31.6%) 127 (30.7%) 80 (36.0%) 0.365
  1. Variables are shown as mean ± SD or n (%). ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; IMT, intima-media thickness; KITT, rate constant for plasma glucose disappearance; LDL-C, low-density lipoprotein cholesterol; MDRD, modification of diet in renal disease equation; SBP, systolic blood pressure; SD, standard deviation; SU, sulfonylurea; TZD, thiazolidinedione
  2. ap values < 0.05 versus no steatosis
  3. bp values < 0.05 versus steatosis only